Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | KDM4A | O75164 | 1/20 | 0.55 |
| ▸ | TDP2 | O95551 | 1/20 | 0.55 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.55 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.55 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5262117 | 0.93 | MAPT (0.62) | MAPTALDH1A1MEN1KMT2AKDM4A | |
| SCHEMBL8028472 | 0.92 | MAPT (0.51) | MAPTALDH1A1MEN1KMT2AKDM4A | |
| SCHEMBL31315669 | 0.91 | MAPT (0.65) | MAPTALDH1A1MEN1KMT2AKDM4A | |
| SCHEMBL6759187 | 0.91 | MAPT (0.65) | MAPTALDH1A1MEN1KMT2AKDM4A | |
| SCHEMBL8328341 | 0.76 | MAPT (0.56) | MAPTALDH1A1MEN1KMT2AKDM4A | |
| SCHEMBL875772 | 0.76 | PDE7A (0.78) | MAPTALDH1A1MEN1KMT2AKDM4A | |
| SCHEMBL31272173 | 0.76 | PDE7A (0.78) | MAPTALDH1A1MEN1KMT2AKDM4A | |
| SCHEMBL224666 | 0.76 | PDE7A (0.60) | MAPTALDH1A1MEN1KMT2AKDM4A | |
| SCHEMBL3384869 | 0.74 | PDE7A (0.58) | MAPTALDH1A1MEN1KMT2AKDM4A | |
| SCHEMBL1896221 | 0.74 | PDE7A (0.58) | MAPTALDH1A1MEN1KMT2AKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359306-B2 | Process for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| CN-103119026-B | Preparation method and the intermediate in this preparation method of the pan-CDK inhibitor of formula (I) | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-19 | — | — | CN | disclosed |
| US-20130245261-A1 | PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| EP-2619186-A1 | PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION | Bayer Pharma Aktiengesellschaft (DE) | 2013-07-31 | — | — | EP | disclosed |
| CN-103119026-A | Process for preparing pan-cdk inhibitors of the formula (l), and intermediates in the preparation | BAYER IP GMBH | 2013-05-22 | — | — | CN | disclosed |
| WO-2012038411-A1 | PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-29 | — | — | WO | disclosed |
| EP-2342185-A1 | SULFONE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS A MEDICINE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010046034-A1 | SULFONE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS A MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245261-A1 | PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION | CDK1, CDK9, CDK6 | MAPT 2896/4885ALDH1A1 3693/4885MEN1 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.